Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP, Research & CSO | August 09, 2022 | August 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date August 09, 2022 · Filed August 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,500 |
Ending reported balance
After 2022-08-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-09 · Exercise / conversion · Acquired 70,177 · Balance 254,584 Row 2 · 2022-08-09 · Exercise / conversion · Acquired 7,916 · Balance 262,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2028-01-26 | Direct | 140,328 |
Reported balance
After 2022-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-09 · Exercise / conversion · Disposed 70,177 · Balance 140,328 F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2029-07-12 | Direct | 125,416 |
Reported balance
After 2022-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-09 · Exercise / conversion · Disposed 7,916 · Balance 125,416 F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2020 Filed Oct 14, 2020 22:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,560 | $43.03 | $239,236.24 |
DisclosureSEC source: 0001209191-20-054833 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.0249 to $43.0302, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,560 | $1.53 | $8,506.80 |
DisclosureSEC source: 0001209191-20-054833 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,510 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-052656 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,875 Underlying: Common Stock · 3,510 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,510 | $38.00 | $133,380.00 |
DisclosureSEC source: 0001209191-20-052656 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,510 | $1.53 | $5,370.30 |
DisclosureSEC source: 0001209191-20-052656 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-052221 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,385 Underlying: Common Stock · 3,700 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,700 | $1.53 | $5,661.00 |
DisclosureSEC source: 0001209191-20-052221 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-051679 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,085 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $31.71 | $120,638.29 |
DisclosureSEC source: 0001209191-20-051679 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-051679 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-049970 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,890 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,340 | $29.98 | $70,147.58 |
DisclosureSEC source: 0001209191-20-049970 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,465 | $30.00 | $43,950.00 |
DisclosureSEC source: 0001209191-20-049970 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,340 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-049970 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2020 Filed Sep 10, 2020 20:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,560 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-049967 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,695 Underlying: Common Stock · 25,560 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 25, 2020 Filed Sep 10, 2020 20:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,560 | $42.92 | $238,632.42 |
DisclosureSEC source: 0001209191-20-049967 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.8999 to $42.9611, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 25, 2020 Filed Sep 10, 2020 20:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 25,560 | $1.53 | $39,106.80 |
DisclosureSEC source: 0001209191-20-049967 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-046369 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,255 Underlying: Common Stock · 7,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $51.08 | $403,562.81 |
DisclosureSEC source: 0001209191-20-046369 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.0414 to $51.1593, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,900 | $1.53 | $12,087.00 |
DisclosureSEC source: 0001209191-20-046369 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2020 Filed Jul 30, 2020 23:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-044060 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,155 Underlying: Common Stock · 7,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 28, 2020 Filed Jul 30, 2020 23:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $47.99 | $379,090.19 |
DisclosureSEC source: 0001209191-20-044060 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.9679 to $48.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 28, 2020 Filed Jul 30, 2020 23:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,900 | $1.53 | $12,087.00 |
DisclosureSEC source: 0001209191-20-044060 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-042653 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,055 Underlying: Common Stock · 7,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $48.85 | $385,876.29 |
DisclosureSEC source: 0001209191-20-042653 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.7897 to $48.8922, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,900 | $1.53 | $12,087.00 |
DisclosureSEC source: 0001209191-20-042653 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,360 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-038791 · doc4.xml · derivative · entry 6 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,955 Underlying: Common Stock · 9,360 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,360 | $48.00 | $449,280.00 |
DisclosureSEC source: 0001209191-20-038791 · doc4.xml · nonDerivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 9,360 | $1.53 | $14,320.80 |
DisclosureSEC source: 0001209191-20-038791 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,560 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-038791 · doc4.xml · derivative · entry 5 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,315 Underlying: Common Stock · 5,560 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,560 | $38.99 | $216,777.73 |
DisclosureSEC source: 0001209191-20-038791 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.8480 to $39.1605, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,560 | $1.53 | $8,506.80 |
DisclosureSEC source: 0001209191-20-038791 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,510 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-038510 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,875 Underlying: Common Stock · 3,510 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,755 | $38.00 | $66,690.00 |
DisclosureSEC source: 0001209191-20-038510 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,755 | $38.00 | $66,694.04 |
DisclosureSEC source: 0001209191-20-038510 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,510 | $1.53 | $5,370.30 |
DisclosureSEC source: 0001209191-20-038510 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-035975 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,385 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $36.28 | $138,030.18 |
DisclosureSEC source: 0001209191-20-035975 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.2691 to $36.2869, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-035975 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 27, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-032330 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,190 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 26, 2020 Filed May 27, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $34.08 | $129,674.40 |
DisclosureSEC source: 0001209191-20-032330 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| May 26, 2020 Filed May 27, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-032330 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,755 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-030596 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,995 Underlying: Common Stock · 1,755 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,755 | $38.00 | $66,690.00 |
DisclosureSEC source: 0001209191-20-030596 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,755 | $1.53 | $2,685.15 |
DisclosureSEC source: 0001209191-20-030596 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-029879 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,750 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $30.07 | $114,418.25 |
DisclosureSEC source: 0001209191-20-029879 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0549 to $30.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:48 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-029879 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.